Welcome to our dedicated page for Mannatech SEC filings (Ticker: MTEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mannatech filings document the regulatory record for an operating health and wellness company that sells nutritional supplements, skin care and anti-aging products, and weight-management products through an independent associate and member network. Periodic and current reports disclose operating results, net sales, gross profit, commissions, foreign currency effects, regional demand, supply chain costs and customer and associate activity.
The company's SEC record also includes proxy materials covering director elections, auditor ratification and executive compensation votes; 8-K reports on financial results and leadership changes; Form 12b-25 late-filing notices; and disclosures related to Nasdaq continued-listing standards and stockholders' equity. These filings describe governance, capital-structure matters, reporting status and risk areas relevant to MTEX common stock.
Mannatech, Inc. director Larry A. Jobe bought additional company stock in the open market. On May 20, 2026, he purchased 2,803 shares of Mannatech common stock at a weighted average price of $4.12 per share, with individual trade prices of $4.15 and $4.03.
After this transaction, Jobe directly owns 70,000 Mannatech shares. The filing notes that the reported price is a weighted average across multiple trades and that detailed trade-by-trade pricing is available on request.
MANNATECH INC director Larry A. Jobe reported an open-market purchase of the company’s common stock. He bought 5,000 shares on May 19, 2026 at a price of $4.20 per share. Following this transaction, he directly holds 67,197 shares of Mannatech common stock.
Mannatech, Inc. director Kevin Andrew Robbins bought additional company stock in the open market. On May 19, 2026, he purchased 7,100 shares of common stock at a weighted average price of $4.17 per share, with trade prices ranging from $4.10 to $4.22. Following these purchases, he directly owns 33,333 shares of Mannatech common stock.
Mannatech, Incorporated reported a return to profitability for the first quarter of 2026. Net sales were $24.9M, down from $26.6M a year earlier, but cost controls and other income led to net income of $0.95M versus a net loss of $1.53M in 2025.
Gross profit was $18.9M and loss from operations narrowed to $0.18M, compared with a $0.83M operating loss a year ago. Diluted earnings per share improved to $0.49 from a diluted loss per share of $0.80, while the company also highlighted constant currency non-GAAP metrics to show underlying trends.
Mannatech, Inc. reported Q1 2026 net sales of $24.9 million, down 6.2% from a year earlier, but swung to net income of $0.95 million versus a prior loss. Gross margin improved to 75.7% on higher pricing and lower inventory charges, and operating cash flow turned positive at $1.1 million. Cash and cash equivalents were $7.0 million with working capital of $1.7 million. However, management discloses conditions that raise substantial doubt about the company’s ability to continue as a going concern and notes noncompliance with a Nasdaq stockholders’ equity requirement. Management is pursuing cost reductions, capital discipline, margin initiatives, and revenue stabilization to address these challenges.
Mannatech, Incorporated has been notified by Nasdaq that it no longer meets the Nasdaq Capital Market’s stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) calls for minimum stockholders’ equity of $2,500,000, but Mannatech reported stockholders’ equity (deficit) of ($5,223,000) as of December 31, 2025, a shortfall of about $7.7 million.
The company also fails alternative continued listing standards tied to market value of listed securities and net income from continuing operations. Mannatech has 45 days from the April 20, 2026 notice, until June 4, 2026, to submit a plan to regain compliance and could receive up to October 17, 2026 to demonstrate compliance if Nasdaq accepts the plan. If Nasdaq rejects the plan, Mannatech may appeal to a Nasdaq Hearings Panel. Beginning April 27, 2026, Nasdaq will identify the company as non-compliant on its website and market data feeds.
Mannatech, Incorporated director Robert Toth has filed a Schedule 13D reporting a 5.1% ownership stake in the company’s common stock. He beneficially owns 99,254 shares, based on 1,929,670 shares outstanding, and holds sole voting and dispositive power over all of these shares.
The position arises from an unrestricted stock grant awarded as part of Mannatech’s director compensation arrangements, with no cash consideration paid by Toth. He states the shares are held for investment and equity compensation purposes and indicates no current plans for major corporate actions, and no additional contracts or arrangements concerning Mannatech securities beyond those described.
Mannatech, Incorporated is asking shareholders to vote at its virtual-only 2026 Annual Shareholders’ Meeting on June 2, 2026. Owners of 1,929,670 common shares as of April 6, 2026 may participate and vote online.
Shareholders will elect two Class III directors (John A. Seifrick and Robert Toth), ratify BDO USA, P.C. as independent auditor for 2026, and cast an advisory Say-on-Pay vote on executive compensation. The proxy details board structure, director and executive pay, significant insider ownership of 47.5% by directors and officers, and related-party transactions, including 16% unsecured loans totaling $3.5 million from Chairman J. Stanley Fredrick and director Tyler Rameson’s Jade Capital LLC, both extended to September 30, 2027.
Mannatech, Incorporated reported weaker results for the fourth quarter and full year 2025. Fourth quarter 2025 net sales were $26.6 million, down 8.2% from 2024, and the company swung from operating income to an operating loss of $0.2 million. Fourth quarter net loss was $11.3 million, or $5.94 per diluted share, compared with net income of $2.3 million a year earlier, largely reflecting unfavorable foreign currency effects and tax items.
For the year ended December 31, 2025, net sales declined to $108.0 million, down 8.3%, with constant-currency sales down 6.8%. Gross margin slipped to 74.9% as supply chain pressures raised product and freight costs. The company posted an operating loss of $0.4 million versus operating income of $1.4 million in 2024.
Full-year net loss was $15.2 million, or $8.00 per diluted share, driven mainly by an income tax provision of $12.3 million, including a non-cash deferred tax charge of $11.5 million. Cash and cash equivalents were $6.2 million at December 31, 2025, and total shareholders’ equity moved to a deficit of $5.2 million.
Mannatech, Incorporated outlines its global wellness business, selling proprietary nutritional supplements, weight-management and skin care products primarily through a network marketing model. The company operates across the Americas, EMEA and Asia/Pacific, and also runs a cross-border e-commerce business in China via its Meitai subsidiary.
As of December 31, 2025, Mannatech reports about 114,000 active associate and preferred customer positions, and notes that commissions and incentives typically range from 35% to 43% of consolidated net sales. The company relies heavily on key products such as Ambrotose Life, TruHealth and Optimal Support Packets and had 170 employees in 2025, down from 189 in 2024.
The report highlights extensive regulatory oversight in the United States and numerous foreign jurisdictions, dependence on third‑party manufacturers and certain unique ingredients, competitive pressure in the nutrition and direct selling industries, and growing risks related to information technology, data protection and the use of artificial intelligence.